EE158 Economic Evaluation of Duvelisib Versus Ofatumumab in Relapsed/Refractory CLL/SLL in Japan
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.457
https://www.valueinhealthjournal.com/article/S1098-3015(24)00572-2/fulltext
Title :
EE158 Economic Evaluation of Duvelisib Versus Ofatumumab in Relapsed/Refractory CLL/SLL in Japan
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00572-2&doi=10.1016/j.jval.2024.03.457
First page :
Section Title :
Open access? :
No
Section Order :
11801